Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Vasodialators Controlled-release-polypeptide-compositions-and-methods-of-treating-inflammatory-bowel-disease

 Inhibitor of ceramidase
It is a general object of the invention to provide a method of selecting compounds that cause ...


 Treatment of bone disorders with adrenomedullin
OF THE INVENTION It is believed that one skilled in the art can, based on the description herein, ...


 99MTC(III) myocardial imaging agents and method of use
OF THE INVENTION The technetium compounds of the present invention which have been found most ...


 1,4-dihydro-4-oxo-3-quinoline derivatives as selectively toxic mammalian antibacterial agents
OF THE INVENTION Compounds of the formula I may be prepared as illustrated in the following ...


 Vaginal sponge delivery system
These and other objects of the invention are achieved in a product which broadly comprises (a) a ...


 Controlled release formulation
What is claimed is: 1. In a controlled release angiotensin converting enzyme inhibitor formulation ...


 Formulations providing three distinct releases
We claim: 1. A therapeutic composition for oral administration consisting essentially of a ...


 Floating sustained release therapeutic compositions
OF THE INVENTION According to the present invention, therapeutic dosage forms have now been ...


 Solid oral dosage forms of ifosfamide
OF PREFERRED EMBODIMENTS The invention is illustrated by the following examples: EXAMPLE 1 I...


 [(benzodioxan, benzofuran or benzopyran) alkylamino] alkyl substituted guanidines
We claim: 1. A compound of the formula: ##STR259## a pharmaceutically acceptable acid addition salt ...


 Controlled release polypeptide compositions and methods of treating inflammatory bowel disease

Details
Inventors: Gombotz, Wayne R.; Wee, SiowFong;
Assignee: Immunex Corporation (Seattle, WA)
Primary Examiner: Ulm; John
Assistant Examiner:
Attorney, Agent or Firm: Smith; Julie K.

The invention pertains to a controlled release pharmaceutical formulation that has an effective amount of a polypeptide selected from the group consisting of: (a) TNFR, (b) IL-1R, (c) IL-1ra, (d) IL-6R and (e) a monoclonal antibody that is immunoreactive against TNF, IL-6 or IL-1; wherein the polypeptide is encapsulated in alginate. The invention also pertains to methods of treating inflammatory bowel disease by administering the above composition to a patient in need thereof.

DETAILED DESCRIPTION OF THE INVENTION The invention described herein is directed to pharmaceutical compositions that provide for the controlled release of an active ingredient in the gastrointestinal cavity of a patient.
Such compositions provide for the delivery of polyleptide material to the lower intestine and comprise an effective amount of a polypeptide selected from the group consisting of: (a) tumor necrosis factor receptor (TNFR), (b) interleukin- 1 receptor (IL-1R), (c) interleukin-1 receptor antagonist (IL-1ra) and (d) a monoclonal antibody that is immunoreactive against TNF, IL-6 or IL- 1; and a salt of an alginic acid.
As used herein, "TNFR" refers to a genus of plasma membrane polypeptides, or fragments thereof, that bind independently with TNF.
Two forms of TNFRs are known in the art and encompassed by this invention, a first TNFR is a 80 kD mature protein described by Smith, et al.
, Science, 248:1019-1022 (1990), incorporated herein by reference.
A second TNFR is a 55-60 kD mature protein and is described in EP-A-0308,378; Schall, et al.
, Cell, 61:361-370 (1990); and Loeicscher, et al.
, Cell, 61:351-359 (1990), each of which is incorporated herein by reference.
The term TNFR as used herein also contemplates the soluble portions or fragments of these two forms, which soluble portions predominantly include the extracellular domain of the proteins, maintain binding activity and which are capable of being secreted by a cell.
Fusion proteins that include a TNFR are also contemplated by this invention.
For example, dimeric fusions of two extracellular domains of the 80 kD TNFR with the constant domain of a human IgG 1 are well known (p80 TNFR:Fc) and is described by Mohler et al.
, J.
Immun.
, 151(3):1548-1561 (1993), incorporated herein by reference.
Similar fusions using the extracellular regions of the 55 kD TNFR with the constant domain of a human IgG 1 are included in this definition, and is described by Peppel, et al.
, J.
Exp.
Med.
, 174:1483-1489 (1991), incorporated herein by reference



Related patents
  Dispersion polymers for ethylene quench water clarification
We claim: 1. A method of removing emulsified oil from ethylene quench water, the method comprising the step of treating the oil-containing water with an effective amount ...
  Corneal angiogenesis inhibitor
What is claimed is: 1. A method for treating corneal neovasculariztion which comprises: administering an effective amount of interferon .beta. for treating corneal ...
  Methods and formulations for use in treating oophorectomized women
OF THE INVENTION Pursuant to the present invention, the regimen comprises a slow-release (or depot) formulation which is effective for an extended period of time. D...
  Treatment of sexual dysfunction in certain patient groups
OF THE INVENTION The present invention relates to methods for the treatment of sexual dysfunction in males and females (including but not limited to erectile ...
  ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST*** *** NO IMAGES AVAILABLE*** Compositions, methods and devices for the transdermal delivery of drugs
OF THE INVENTION The present invention provides compositions comprising (i) a gelling agent consisting of methylcellulose or at least one natural gum, or a mixture ...
  Treatment of sexual dysfunction in certain patient groups
OF THE INVENTION The present invention relates to methods for the treatment of sexual dysfunction in males and females (including but not limited to erectile ...
  Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
This invention is therefore aimed at solving the above-mentioned shortcoming of adenosinergic approaches, while obtaining either analgesic (anesthetic) or protective ...
  Oil composition
What is claimed is: 1. An oil composition, comprising about 0.1 to 59.8% by weight of a triglyceride, about 40 to 99.7% by weight of a diglyceride, about 0.1 to 10% by ...
  Blocking agents of EDRF effect or formation for the treatment of shock
We claim: 1. A therapeutical composition of matter for the treatment by perfusion of shock states comprising as an essential ingredient therein an effective amount of a ...
  Use of polyamines as ionic-channel regulating agents
OF THE PREFERRED EMBODIMENTS The disclosure of any and all cited documents including literature and patent application is incorporated by reference in its entirety. It ...

0.004

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved